Literature DB >> 22949431

Trastuzumab and congestive heart failure: what can we learn from use in the community?

Ann M Geiger.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22949431      PMCID： PMC3840575          DOI： 10.1093/jnci/djs342

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  8 in total

1.  Trastuzumab in the treatment of breast cancer.

Authors:  Gabriel N Hortobagyi
Journal:  N Engl J Med       Date:  2005-10-20       Impact factor: 91.245

Review 2.  Cost-effectiveness of trastuzumab as adjuvant therapy for early breast cancer: a systematic review.

Authors:  Agnes L F Chan; Henry W C Leung; Chin-Li Lu; Shun Jin Lin
Journal:  Ann Pharmacother       Date:  2009-02-03       Impact factor: 3.154

3.  Clinical trials in the era of personalized oncology.

Authors:  Michael L Maitland; Richard L Schilsky
Journal:  CA Cancer J Clin       Date:  2011-10-27       Impact factor: 508.702

4.  Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer.

Authors:  Aman U Buzdar; Nuhad K Ibrahim; Deborah Francis; Daniel J Booser; Eva S Thomas; Richard L Theriault; Lajos Pusztai; Marjorie C Green; Banu K Arun; Sharon H Giordano; Massimo Cristofanilli; Debra K Frye; Terry L Smith; Kelly K Hunt; Sonja E Singletary; Aysegul A Sahin; Michael S Ewer; Thomas A Buchholz; Donald Berry; Gabriel N Hortobagyi
Journal:  J Clin Oncol       Date:  2005-02-28       Impact factor: 44.544

Review 5.  Trastuzumab containing regimens for early breast cancer.

Authors:  Lorenzo Moja; Ludovica Tagliabue; Sara Balduzzi; Elena Parmelli; Vanna Pistotti; Valentina Guarneri; Roberto D'Amico
Journal:  Cochrane Database Syst Rev       Date:  2012-04-18

6.  Cardiac dysfunction in the trastuzumab clinical trials experience.

Authors:  Andrew Seidman; Clifford Hudis; Mary Kathryn Pierri; Steven Shak; Virginia Paton; Mark Ashby; Maureen Murphy; Stanford J Stewart; Deborah Keefe
Journal:  J Clin Oncol       Date:  2002-03-01       Impact factor: 44.544

7.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.

Authors:  Edward H Romond; Edith A Perez; John Bryant; Vera J Suman; Charles E Geyer; Nancy E Davidson; Elizabeth Tan-Chiu; Silvana Martino; Soonmyung Paik; Peter A Kaufman; Sandra M Swain; Thomas M Pisansky; Louis Fehrenbacher; Leila A Kutteh; Victor G Vogel; Daniel W Visscher; Greg Yothers; Robert B Jenkins; Ann M Brown; Shaker R Dakhil; Eleftherios P Mamounas; Wilma L Lingle; Pamela M Klein; James N Ingle; Norman Wolmark
Journal:  N Engl J Med       Date:  2005-10-20       Impact factor: 91.245

8.  Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study.

Authors:  Erin J Aiello Bowles; Robert Wellman; Heather Spencer Feigelson; Adedayo A Onitilo; Andrew N Freedman; Thomas Delate; Larry A Allen; Larissa Nekhlyudov; Katrina A B Goddard; Robert L Davis; Laurel A Habel; Marianne Ulcickas Yood; Catherine McCarty; David J Magid; Edward H Wagner
Journal:  J Natl Cancer Inst       Date:  2012-09-05       Impact factor: 13.506
  8 in total
  1 in total

Review 1.  Understanding cardiovascular injury after treatment for cancer: an overview of current uses and future directions of cardiovascular magnetic resonance.

Authors:  Sujethra Vasu; W Gregory Hundley
Journal:  J Cardiovasc Magn Reson       Date:  2013-07-31       Impact factor: 5.364
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.